Drug Profile
ALS 2158
Alternative Names: ALS-002158; ALS-2158Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Developer Alios BioPharma; Vertex Pharmaceuticals
- Class Adenine nucleotides; Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 25 Sep 2012 Discontinued - Phase-I for Hepatitis C (treatment-naive patients) in New Zealand, Australia (PO)
- 09 Dec 2011 Phase-I clinical trials in Hepatitis C (treatment-naive patients) in New Zealand (PO) (NCT01554085)
- 09 Dec 2011 Phase-I clinical trials in Hepatitis C (treatment-naive patients) in Australia (PO)